10-QPeriod: Q2 FY2024

INTUITIVE SURGICAL INC Quarterly Report for Q2 Ended Jun 30, 2024

Filed July 19, 2024For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported strong revenue growth in the second quarter of 2024, with total revenue increasing by 14% year-over-year to $2.01 billion. This growth was driven by robust performance in instruments and accessories, systems, and services, fueled by a 17% increase in da Vinci procedures and an impressive 82% surge in Ion procedures. The company also saw a healthy 14% increase in da Vinci system placements and a significant 56% expansion in its Ion system installed base. Profitability metrics improved, with gross profit margin increasing to 68.3% and operating income growing by 22%. The company maintains a strong balance sheet with $7.68 billion in cash, cash equivalents, and investments, indicating solid financial health and capacity for continued investment in growth and innovation.

Financial Highlights

46 data points
Beta

Revenue

$2.01B

68.3% Gross Margin

Net Income

$526.90M

26.2% Net Margin

EPS (Diluted)

$1.46

Total Assets

$16.65B

Cash & Equivalents

$3.04B

Free Cash Flow

$620.50M

Financial Statements
Beta
Revenue$2.01B
Cost of Revenue$637.20M
Gross Profit$1.37B
R&D Expenses$280.10M
SG&A Expenses$525.30M
Operating Expenses$805.40M
Operating Income$567.30M
Net Income$526.90M
EPS (Basic)$1.48
EPS (Diluted)$1.46
Shares Outstanding (Basic)355.00M
Shares Outstanding (Diluted)361.00M

Key Highlights

  • 1Total revenue increased by 14% to $2.01 billion in Q2 2024, driven by strong product and service revenue.
  • 2Da Vinci procedures grew 17% year-over-year, demonstrating continued adoption and utilization of the company's core robotic surgical systems.
  • 3Ion endoluminal system procedures saw substantial growth, increasing by 82% year-over-year, indicating strong market traction for this newer product line.
  • 4Systems revenue grew 14%, supported by a 14% increase in da Vinci system placements and a 56% increase in the Ion system installed base.
  • 5Gross profit margin improved to 68.3% from 66.7% in the prior year's comparable quarter.
  • 6Operating income increased by 22% to $567 million, reflecting effective cost management and revenue growth.
  • 7The company ended the quarter with a robust cash position of $7.68 billion, providing ample liquidity for future investments and operations.

Frequently Asked Questions

Revenue growth was primarily driven by a 15% increase in product revenue, fueled by a 16% rise in instruments and accessories revenue and a 14% increase in systems revenue. Service revenue also contributed with a 10% increase. This was underpinned by strong growth in da Vinci procedures (17%) and a significant surge in Ion procedures (82%), alongside an increase in da Vinci system placements and the Ion system installed base.

The da Vinci 5 system is in the early stages of launch, and the company placed 70 da Vinci 5 systems in the second quarter of 2024. While still early, this new system contributed to the overall increase in system placements and is part of the company's strategy for next-generation robotic systems.

Intuitive Surgical maintains a strong financial position with $7.68 billion in cash, cash equivalents, and investments as of June 30, 2024. The company expects continued growth, though it acknowledges potential impacts from macroeconomic and geopolitical headwinds, supply chain risks, and hospital financial pressures. They plan to fund significant capital investments ($1 billion to $1.2 billion in 2024) primarily through cash generated from operations.

The company is involved in ongoing product liability lawsuits, patent litigation, and commercial litigation, including antitrust claims related to instrument service and repair. While some past legal matters have been resolved, the company notes that the outcomes of current and future legal proceedings are uncertain and could potentially have a material adverse effect on its business, financial condition, or results of operations. The company is also subject to various regulatory requirements globally for its medical devices.